FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia - Wikidata - awgldk - TriplyDB

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

http://www.wikidata.org/entity/Q33404894

about

Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India.DNA microarray analysis of genes differentially expressed in adipocyte differentiation.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.

P2860

Q26801945-6FCB5C86-AA8D-4227-AED9-33C3792E573D Q38914342-9CC543EA-EC0E-4126-883E-7DECED46C085 Q38993294-5A9E3361-7DD7-493F-A26F-EE2C02BA3D17 Q41402735-9CA080E6-06B1-4A78-9FEB-053CA66C61AD

P2860

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

http://www.wikidata.org/entity/Q33404894

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@ast

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@en

type

label

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@ast

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@en

prefLabel

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@ast

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@en

P1433

Q33404894-1486D4AC-EFAA-4F34-885A-A173E32B7BA3

P1476

Q33404894-B66E8088-6367-4180-A87A-21C242FCDCBF

P2093

Q33404894-0BD1A96F-A33E-4ED5-A599-70D1920F2693

Q33404894-73A7F35B-8473-4FDB-BF20-02AFFD7FCE50

Q33404894-7594ECB2-1544-4067-A80C-06AC297317E7

Q33404894-821C4C59-2525-4064-AC49-5FBDCC22A80E

Q33404894-9D3DB26D-6137-40B0-9B61-8C2EF1FEF0B5

Q33404894-F805C589-EE15-410D-BB46-1EBCD9EB1B7C

P2860

Q33404894-0679C2A0-8956-4EF0-A8A9-B0C38CC33B0A

Q33404894-06D88801-FAAF-49A4-BC59-7BF24AB6A77D

Q33404894-42B5FD63-20CA-4E1A-B049-C79532354052

Q33404894-5E7B49D5-562B-4209-AFFC-C0B34CB4B92A

Q33404894-64D39B6A-2DF1-4326-BE55-BD8E08FD1BFD

Q33404894-776272E8-4286-4D28-8A3B-0CE8DFC34DA0

Q33404894-7D14D6DD-7F1C-4AD6-A361-3729CD948B09

Q33404894-8605448F-FF5D-4773-9982-8BF4867F19C1

Q33404894-86F9CE87-125E-4EA6-ACFE-08B794ABCF0C

Q33404894-8B45BC1A-9586-4DAB-8DE3-FD502A6C6E7F

P2888

Q33404894-F91651FC-1138-4D43-B379-0CE31967C0B8

P304

Q33404894-7EA4FC06-D85A-4DB3-84A4-3E79AA21955F

P31

Q33404894-B5FAF72E-190C-461B-B51A-BEB34977532C

P356

Q33404894-80D01A2D-7064-4698-971D-2BFEDA3C0646

P478

Q33404894-246427AE-5D53-4EB0-AEEC-627EB4D6A299

P577

Q33404894-A2FE51D4-CE6A-458A-9935-4CBD5F1828C5

P5875

Q33404894-E1FBB7E3-44AD-4FD1-80D6-FD67F50FF536

P6179

Q33404894-B26CC574-79A5-4D13-9CC0-D5DD9ED77ACF

P698

Q33404894-13CE1C1C-AC52-4AFE-B10A-BF4489F58398

P932

Q33404894-314323B8-06A3-4D52-80B9-CC6719F69422

P356

P1433

BMC Blood Disorders

P1476

FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia

@en

P2093

Emmanouil Papadakis

http://www.w3.org/2001/XMLSchema#string

Fani Kalala

http://www.w3.org/2001/XMLSchema#string

Gedeon Loules

http://www.w3.org/2001/XMLSchema#string

Matthaios Speletas

http://www.w3.org/2001/XMLSchema#string

Nikolaos Giannakoulas

http://www.w3.org/2001/XMLSchema#string

Panagiota Matsouka

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Recent advances in the diagnosis and treatment of hypereosinophilic syndromes.

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Hypereosinophilic syndrome: an update.

P2888

P304

1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2326-9-1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23971656

http://www.w3.org/2001/XMLSchema#string

P6179

1015191679

http://www.w3.org/2001/XMLSchema#string

P698

19187542

http://www.w3.org/2001/XMLSchema#string

P932

2640376

http://www.w3.org/2001/XMLSchema#string